<p>Portside Wealth Group LLC 在最近向证券交易委员会（SEC）披露的文件中表示，在第四季度将其在雅培（NYSE:ABT - 免费报告）股票中的持股比例削减了 41.8%。该机构投资者在该季度出售了 13,652 股后，持有 19,016 股这家医疗产品制造商的股票。根据其最近的 SEC 文件，Portside Wealth Group LLC 在雅培的持股价值为 2,382,000 美元。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>AbbVie 的前景：二月份的下跌看起来像是买入信号</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也调整了对 ABT 的持股。Lakeshore Capital Group Inc. 在第四季度将其在雅培的持股增加了 4.0%。Lakeshore Capital Group Inc. 目前拥有 7,367 股这家医疗产品制造商的股票，价值 923,000 美元，此前在上个季度又增持了 280 股。Sound Income Strategies LLC 在第四季度将其在雅培的持股增加了 6.8%。Sound Income Strategies LLC 目前拥有 2,130 股这家医疗产品制造商的股票，价值 259,000 美元，此前在上个季度又增持了 135 股。Rathbones Group PLC 在第四季度将其在雅培的持股增加了 3.6%。Rathbones Group PLC 目前拥有 3,116,386 股这家医疗产品制造商的股票，价值 390,452,000 美元，此前在上个季度又增持了 107,648 股。Guild Investment Management Inc. 在第四季度购买了雅培的新股份，价值约 202,000 美元。最后，Buffalo Business &amp; Estate Services Ltd. 在第四季度购买了雅培的新股份，价值约 280,000 美元。目前，75.18% 的股票由机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<p>几位股票研究分析师最近对 ABT 股票进行了评估。Piper Sandler 在 1 月 23 日的研究报告中将雅培的目标价从 150.00 美元下调至 135.00 美元，并对该公司给予了 “增持” 评级。花旗集团在 3 月 11 日的报告中将雅培的目标价从 140.00 美元下调至 136.00 美元，并对该公司给予了 “买入” 评级。加拿大皇家银行在 1 月 23 日的报告中将雅培的目标价从 147.00 美元下调至 135.00 美元，并对该公司给予了 “跑赢大盘” 评级。Weiss Ratings 在 1 月 26 日的报告中将雅培的评级从 “买入（b-）” 下调至 “持有（c+）”。最后，Oppenheimer 在 1 月 23 日的报告中将雅培的目标价从 140.00 美元下调至 132.00 美元，并对该公司给予了 “跑赢大盘” 评级。两位投资分析师对该股票给予了强烈买入评级，十五位给予了买入评级，四位给予了持有评级。根据 MarketBeat.com 的数据，雅培目前的平均评级为 “适度买入”，平均目标价为 135.68 美元。</p>
<ul>
<li>雅培一月份的回调是否是一个好的买入时机？</li>
</ul>
<p><strong>阅读我们对 ABT 的最新分析</strong></p>
<h2>雅培股票表现</h2>
<p>ABT 的股票在周二开盘价为 102.30 美元。该公司的债务与股本比率为 0.19，流动比率为 1.58，速动比率为 1.18。雅培的股价在一年内最低为 100.88 美元，最高为 139.06 美元。该公司的市值为 1781.6 亿美元，市盈率为 27.50，市盈增长比率为 1.64，贝塔值为 0.79。该公司的 50 日移动平均线为 109.35 美元，200 日移动平均线为 120.71 美元。</p>
<ul>
<li>2 家医疗公司可能会因盈利而获得大幅提升</li>
</ul>
<p>雅培（NYSE:ABT - 获取免费报告）最近在 1 月 22 日宣布了其财报。该医疗产品制造商报告每股收益（EPS）为 1.50 美元，符合市场共识预期的 1.50 美元。该公司在本季度的收入为 114.6 亿美元，而分析师预期为 118 亿美元。雅培的股本回报率为 17.73%，净利润率为 14.72%。该公司的季度收入同比增长 4.4%。在去年同期，该公司每股收益为 1.34 美元。雅培已将其 2026 年第一季度的指导目标设定为 1.120-1.180 EPS，2026 财年的指导目标设定为 5.550-5.800 EPS。整体来看，卖方分析师预计雅培在当前年度将发布 5.14 EPS。</p>
<h2>雅培宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，将于 5 月 15 日（星期五）支付。4 月 15 日（星期三）登记在册的股东将获得 0.63 美元的分红。这相当于每年 2.52 美元的分红，收益率为 2.5%。该分红的除息日期为 4 月 15 日（星期三）。雅培的分红支付比率（DPR）目前为 67.74%。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，执行副总裁 Daniel Gesua Sive Salvadori 于 3 月 2 日星期一出售了 885 股公司的股票。股票以平均价格 115.58 美元出售，总交易额为 102,288.30 美元。出售完成后，这位执行副总裁持有 146,377 股公司的股票，价值 16,918,253.66 美元。此次交易使其持股减少了 0.60%。该出售在向 SEC 的法律文件中披露，相关信息可通过此链接获取。此外，副总裁 John A. Jr. Mccoy 于 3 月 2 日星期一出售了 585 股公司的股票。股票以平均价格 115.58 美元出售，总交易额为 67,614.30 美元。出售后，这位副总裁直接持有 24,628 股公司的股票，价值约为 2,846,504.24 美元。此次交易使其持股减少了 2.32%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士出售了 3,055 股公司股票，价值 353,097 美元。目前公司内部人士持有 0.46% 的股票。</p>
<h2>雅培公司简介</h2>
<p>（免费报告）</p>
<p>雅培是一家全球医疗保健公司，总部位于伊利诺伊州的阿博特公园，开发、制造和销售广泛的医疗产品和服务。雅培成立于 1888 年，通过多个业务领域运营，专注于诊断、医疗设备、营养品和成熟药品。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
<p>在诊断方面，雅培提供实验室和现场检测平台及试剂，用于检测传染病、慢性疾病和生物标志物；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过雅培</li>
</ul>
<p><strong>想知道其他对 ABT 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在雅培吗？</h2>
<p>在考虑雅培之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而雅培不在名单上。</p>
<p>虽然雅培目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

标普全球医疗股指数 ETF - iShares

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

医疗业 ETF - Vanguard

医疗业 ETF - SPDR

美国制药 ETF - iShares

雅培

<p>Portside Wealth Group LLC 在第四季度减少了对雅培（NYSE:ABT）的持股比例，下降了 41.8%，出售了 13,652 股，剩余 19,016 股，价值 238 万美元。其他机构投资者也调整了他们的持股。分析师们下调了雅培的目标股价，平均目标为 135.68 美元。雅培的股票开盘价为 102.30 美元，市值为 1781.6 亿美元。该公司报告第四季度每股收益为 1.50 美元，符合预期，并宣布将于 5 月 15 日支付季度股息</p>

<p>Portside Wealth Group LLC cut its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 41.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,016 shares of the healthcare product maker's stock after selling 13,652 shares during the quarter. Portside Wealth Group LLC's holdings in Abbott Laboratories were worth $2,382,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Portside Wealth Group LLC 在最近向证券交易委员会（SEC）披露的文件中表示，在第四季度将其在雅培（NYSE:ABT - 免费报告）股票中的持股比例削减了 41.8%。该机构投资者在该季度出售了 13,652 股后，持有 19,016 股这家医疗产品制造商的股票。根据其最近的 SEC 文件，Portside Wealth Group LLC 在雅培的持股价值为 2,382,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 的前景：二月份的下跌看起来像是买入信号</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also recently modified their holdings of ABT. Lakeshore Capital Group Inc. increased its position in shares of Abbott Laboratories by 4.0% during the fourth quarter. Lakeshore Capital Group Inc. now owns 7,367 shares of the healthcare product maker's stock valued at $923,000 after acquiring an additional 280 shares in the last quarter. Sound Income Strategies LLC increased its position in shares of Abbott Laboratories by 6.8% during the fourth quarter. Sound Income Strategies LLC now owns 2,130 shares of the healthcare product maker's stock valued at $259,000 after acquiring an additional 135 shares in the last quarter. Rathbones Group PLC increased its position in shares of Abbott Laboratories by 3.6% during the fourth quarter. Rathbones Group PLC now owns 3,116,386 shares of the healthcare product maker's stock valued at $390,452,000 after acquiring an additional 107,648 shares in the last quarter. Guild Investment Management Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $202,000. Finally, Buffalo Business &amp; Estate Services Ltd. bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $280,000. 75.18% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也调整了对 ABT 的持股。Lakeshore Capital Group Inc. 在第四季度将其在雅培的持股增加了 4.0%。Lakeshore Capital Group Inc. 目前拥有 7,367 股这家医疗产品制造商的股票，价值 923,000 美元，此前在上个季度又增持了 280 股。Sound Income Strategies LLC 在第四季度将其在雅培的持股增加了 6.8%。Sound Income Strategies LLC 目前拥有 2,130 股这家医疗产品制造商的股票，价值 259,000 美元，此前在上个季度又增持了 135 股。Rathbones Group PLC 在第四季度将其在雅培的持股增加了 3.6%。Rathbones Group PLC 目前拥有 3,116,386 股这家医疗产品制造商的股票，价值 390,452,000 美元，此前在上个季度又增持了 107,648 股。Guild Investment Management Inc. 在第四季度购买了雅培的新股份，价值约 202,000 美元。最后，Buffalo Business &amp; Estate Services Ltd. 在第四季度购买了雅培的新股份，价值约 280,000 美元。目前，75.18% 的股票由机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several equities research analysts recently weighed in on ABT shares. Piper Sandler reduced their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an &#34;overweight&#34; rating for the company in a research report on Friday, January 23rd. Citigroup reduced their price objective on Abbott Laboratories from $140.00 to $136.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, March 11th. Royal Bank Of Canada reduced their price objective on Abbott Laboratories from $147.00 to $135.00 and set an &#34;outperform&#34; rating for the company in a report on Friday, January 23rd. Weiss Ratings downgraded Abbott Laboratories from a &#34;buy (b-)&#34; rating to a &#34;hold (c+)&#34; rating in a report on Monday, January 26th. Finally, Oppenheimer reduced their price objective on Abbott Laboratories from $140.00 to $132.00 and set an &#34;outperform&#34; rating for the company in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $135.68.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对 ABT 股票进行了评估。Piper Sandler 在 1 月 23 日的研究报告中将雅培的目标价从 150.00 美元下调至 135.00 美元，并对该公司给予了 “增持” 评级。花旗集团在 3 月 11 日的报告中将雅培的目标价从 140.00 美元下调至 136.00 美元，并对该公司给予了 “买入” 评级。加拿大皇家银行在 1 月 23 日的报告中将雅培的目标价从 147.00 美元下调至 135.00 美元，并对该公司给予了 “跑赢大盘” 评级。Weiss Ratings 在 1 月 26 日的报告中将雅培的评级从 “买入（b-）” 下调至 “持有（c+）”。最后，Oppenheimer 在 1 月 23 日的报告中将雅培的目标价从 140.00 美元下调至 132.00 美元，并对该公司给予了 “跑赢大盘” 评级。两位投资分析师对该股票给予了强烈买入评级，十五位给予了买入评级，四位给予了持有评级。根据 MarketBeat.com 的数据，雅培目前的平均评级为 “适度买入”，平均目标价为 135.68 美元。</p>
</div><ul>
<li>Is Abbott’s January Pullback a Good Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培一月份的回调是否是一个好的买入时机？</li>
</ul>
</div><p><strong>Read Our Latest Analysis on ABT</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 ABT 的最新分析</strong></p>
</div><h2>Abbott Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>雅培股票表现</h2>
</div><p>Shares of ABT opened at $102.30 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a one year low of $100.88 and a one year high of $139.06. The firm has a market capitalization of $178.16 billion, a P/E ratio of 27.50, a PEG ratio of 1.64 and a beta of 0.79. The business has a fifty day moving average of $109.35 and a 200 day moving average of $120.71.</p>
<div class="lb-trans"><p>ABT 的股票在周二开盘价为 102.30 美元。该公司的债务与股本比率为 0.19，流动比率为 1.58，速动比率为 1.18。雅培的股价在一年内最低为 100.88 美元，最高为 139.06 美元。该公司的市值为 1781.6 亿美元，市盈率为 27.50，市盈增长比率为 1.64，贝塔值为 0.79。该公司的 50 日移动平均线为 109.35 美元，200 日移动平均线为 120.71 美元。</p>
</div><ul>
<li>2 Healthcare Names That Could Get a Big Boost From Earnings</li>
</ul>
<div class="lb-trans"><ul>
<li>2 家医疗公司可能会因盈利而获得大幅提升</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. The business had revenue of $11.46 billion for the quarter, compared to analysts' expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business's revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）最近在 1 月 22 日宣布了其财报。该医疗产品制造商报告每股收益（EPS）为 1.50 美元，符合市场共识预期的 1.50 美元。该公司在本季度的收入为 114.6 亿美元，而分析师预期为 118 亿美元。雅培的股本回报率为 17.73%，净利润率为 14.72%。该公司的季度收入同比增长 4.4%。在去年同期，该公司每股收益为 1.34 美元。雅培已将其 2026 年第一季度的指导目标设定为 1.120-1.180 EPS，2026 财年的指导目标设定为 5.550-5.800 EPS。整体来看，卖方分析师预计雅培在当前年度将发布 5.14 EPS。</p>
</div><h2>Abbott Laboratories Announces Dividend</h2>
<div class="lb-trans"><h2>雅培宣布分红</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 67.74%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 5 月 15 日（星期五）支付。4 月 15 日（星期三）登记在册的股东将获得 0.63 美元的分红。这相当于每年 2.52 美元的分红，收益率为 2.5%。该分红的除息日期为 4 月 15 日（星期三）。雅培的分红支付比率（DPR）目前为 67.74%。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president owned 146,377 shares of the company's stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP John A. Jr. Mccoy sold 585 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the sale, the vice president directly owned 24,628 shares of the company's stock, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Daniel Gesua Sive Salvadori 于 3 月 2 日星期一出售了 885 股公司的股票。股票以平均价格 115.58 美元出售，总交易额为 102,288.30 美元。出售完成后，这位执行副总裁持有 146,377 股公司的股票，价值 16,918,253.66 美元。此次交易使其持股减少了 0.60%。该出售在向 SEC 的法律文件中披露，相关信息可通过此链接获取。此外，副总裁 John A. Jr. Mccoy 于 3 月 2 日星期一出售了 585 股公司的股票。股票以平均价格 115.58 美元出售，总交易额为 67,614.30 美元。出售后，这位副总裁直接持有 24,628 股公司的股票，价值约为 2,846,504.24 美元。此次交易使其持股减少了 2.32%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士出售了 3,055 股公司股票，价值 353,097 美元。目前公司内部人士持有 0.46% 的股票。</p>
</div><h2>Abbott Laboratories Company Profile</h2>
<div class="lb-trans"><h2>雅培公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.</p>
<div class="lb-trans"><p>雅培是一家全球医疗保健公司，总部位于伊利诺伊州的阿博特公园，开发、制造和销售广泛的医疗产品和服务。雅培成立于 1888 年，通过多个业务领域运营，专注于诊断、医疗设备、营养品和成熟药品。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
</div><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p>
<div class="lb-trans"><p>在诊断方面，雅培提供实验室和现场检测平台及试剂，用于检测传染病、慢性疾病和生物标志物；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过雅培</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 ABT 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在雅培吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑雅培之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而雅培不在名单上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Portside Wealth Group LLC 出售雅培实验室 13,652 股股份 $ABT